Socialpost

Complete News World

Nicola Mining has signed a purchase agreement for gold and silver concentrate with Ocean Partners Holdings

Novamind announces the suspension of trading and the resumption of trading

toronto, run / 8. November 2021 /NovaMind Company (Custom search engine: NM | OTCQB: NVMDF | FWB: HN2) (“Novamind” or “the Company”), a leading mental health company specializing in psychedelic medicine, gDeclares that the Ontario Securities Commission (“OSC“) the originalh am 3. Trading halt imposed in November 2021 (stop trade orderAnd The CTO”) is completely cancelledn hat.

CTO was imposed due to dThe company failed to prepare audited annual financial statements, management report (Management discussion and analysis) and the corresponding certificates for the fiscal year ending on the 30th. June 2021 (Din another meaningAnnual ReportNS‘) to be presented. CompanyNSen Now he has all the mailThe required documents have been submitted. Annual reports can be viewed through the company’s SEDAR profilenter www.sedar.com can be seen.

Ordinary stock now wAdmit to trading on the Canadian Stock Exchange again.

About NovaMind

NovaMind is a leading mental health company, providing secure access to psychedelic medications through a network of clinics and clinical research sites. NovaMind is a provider of ketamine-based psychotherapy and other types of new therapies through its network of Cedar Psychiatry Clinics. The company also operates Cedar Clinical Research, a contract research organization that specializes in clinical trials and evidence-based research for psychedelic medicine. Cedar Psychiatry and Cedar Clinical Research are both wholly owned by Novamind. For more information on how Novamind can improve mental well-being and accompany people throughout the recovery process, visit novamind.ca.

caller data

NovaMind

Yaron Konforti, CEO and Director

Tel .: +1 (647) 953 9512

See also  Soundings between the pilots and Lufthansa were unsuccessful

Samantha Dillardo, Vice President of Communications

NSNSdisturb: [email protected]

Bill Mitolas, Investor Relations

email: [email protected]

forward-looking statements

This press release contains forward-looking statements. All statements in this release that are not based on historical facts are forward-looking statements and involve risks and uncertainties. There can be no guarantee that such statements will prove correct. Actual results and future events could differ materially from these statements. Important factors that may cause actual results to differ materially from the Company’s expectations, including risks that may arise from time to time To be included in the company’s public notices. Readers are cautioned that the forward-looking information is not reliable. The forward-looking statements contained in this press release are expressly limited to this cautionary note. The forward-looking statements contained in this press release are effective as of the date of this press release. The Company is not bound by this forward-looking statementn To publicly update or correct the data, either as a result of new information, future events or for any other reason, unless expressly required by applicable laws.

The source language (usually English) in which the original text is published is the official, authorized and legally valid version. This translation is included for better understanding. The German version can be abbreviated or abbreviated. We assume no responsibility or liability for the content, correctness, suitability or accuracy of this translation. From the translator’s point of view, the message does not constitute a buy or sell recommendation! Please note the original English letter in www.sedar.comAnd www.sec.govAnd www.asx.com.au/ Or on the company’s website!

See also  René Benko's Cigna bankruptcy: criticism of Olaf Schulz - Did Gusenbauer arrange the deal?